Celcuity (CELC) Other Accumulated Expenses (2018 - 2026)
Celcuity's (CELC) quarterly Other Accumulated Expenses came in at $20.9 million in Q4 2025, up 280.96% YoY from $5.5 million in Q4 2024, and up 280.96% on a QoQ basis from $5.5 million in Q4 2024.
Powered by 
Analysis
Celcuity (CELC) Other Accumulated Expenses (2018 - 2026) Analysis & Trends
Celcuity (CELC) has 4 years of Other Accumulated Expenses data on file, last reported at $20.9 million in Q4 2025.
- Quarterly Other Accumulated Expenses rose 280.96% year-over-year to $20.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $20.9 million (up 280.96% YoY) and the FY2025 annual result came in at $20.9 million, up 280.96% from the prior year.
- Other Accumulated Expenses grew to $20.9 million in Q4 2025, from $5.5 million in the prior quarter.
- In the past five years, Other Accumulated Expenses ranged from a high of $20.9 million in Q4 2025 to a low of $5.5 million in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Celcuity | 5.25 Bn | 5.25 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 20.58 Mn |
| Dec 31, 2025 | 15.87 Mn |
| Dec 31, 2024 | 5.48 Mn |
| Dec 31, 2019 | 112,746.00 |
| Dec 31, 2018 | 52,347.00 |